Adicet bio to present at the american society of gene & cell therapy's (asgct) 2024 advancing gene + cell therapies for cancer conference

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming american society of gene & cell therapy's (asgct) 2024 advancing gene and cell therapies for cancer conference, taking place october 16 – 17, 2024, in philadelphia, pa. details of the oral presentation are.
ACET Ratings Summary
ACET Quant Ranking